{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:48:25Z","timestamp":1794448105727,"version":"4.9.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.heliyon.2024.e39698","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:42:33Z","timestamp":1729568553000},"page":"e39698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia"],"prefix":"10.1016","volume":"10","author":[{"given":"Wee-Joo","family":"Chng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Blunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmohan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e39698_bib1","first-page":"730","article-title":"High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome, Indian","volume":"149","author":"Kumar","year":"2019","journal-title":"J. Media Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","article-title":"Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e39698_bib3","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med. Sci. Basel. Switz."},{"key":"10.1016\/j.heliyon.2024.e39698_bib4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib7","first-page":"52","article-title":"Korean multiple myeloma working party, multiple myeloma in Korea: past, present, and future perspectives","volume":"92","author":"Lee","year":"2010","journal-title":"Experience of the Korean Multiple Myeloma Working Party, Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib8","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/S1470-2045(13)70404-2","article-title":"Management of multiple myeloma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e39698_bib10","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e39698_bib11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib12","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of proteasome inhibition for extending remissions (APEX) investigators, bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib13","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e39698_bib14","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-Melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061808","article-title":"Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol","volume":"12","author":"Cantadori","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2024.e39698_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106167","article-title":"Limiting factors for autologous transplantation among transplant-eligible multiple myeloma patients: lesson from a Tertiary Cancer Centre in rural India","volume":"83","author":"Nair","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/bmt.2016.43","article-title":"Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group, Bone","volume":"51","author":"Ong","year":"2016","journal-title":"Marrow. Transplant."},{"key":"10.1016\/j.heliyon.2024.e39698_bib18","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment, the","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib19","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e39698_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib22","first-page":"1","article-title":"Total marrow irradiation as part of autologous stem cell transplantation for asian patients with multiple myeloma","volume":"2013","author":"Lin","year":"2013","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2024.e39698_bib23","article-title":"Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: a nationwide population-based study and a single-institute analysis","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e39698_bib24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23822","article-title":"A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma: combination therapy with CPT plus thalidomide in RRMM patients","volume":"89","author":"Geng","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib25","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1111\/ajco.12609","article-title":"Therapeutic experience of vincristine\/cyclophosphamide\/melphalan or mitoxantrone\/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China","volume":"13","author":"Wang","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00029330-200703020-00005","article-title":"Modified conditioning regimen \\busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma","volume":"120","author":"Zhang","year":"2007","journal-title":"Chin. Med. J. (Engl)."},{"key":"10.1016\/j.heliyon.2024.e39698_bib27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3109\/10428194.2014.887711","article-title":"Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed\/refractory multiple myeloma with severe heart failure","volume":"55","author":"Zhou","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e39698_bib28","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12162","article-title":"A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma","volume":"7","author":"Wei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e39698_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.leukres.2010.01.011","article-title":"Role of the TNF-\u03b1 promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone","volume":"34","author":"Du","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00277-018-3370-1","article-title":"Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma","volume":"97","author":"Aggarwal","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib32","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.7314\/APJCP.2012.13.9.4777","article-title":"Clinical study of thalidomide combined with dexamethasone for the treatment of elderly patients with newly diagnosed multiple myeloma, asian","volume":"13","author":"Chen","year":"2012","journal-title":"Pac. J. Cancer. Prev."},{"key":"10.1016\/j.heliyon.2024.e39698_bib33","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S2152-2650(21)02319-3","article-title":"P-192: circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed\/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study, Clin. Lymphoma","volume":"21","author":"Chen","year":"2021","journal-title":"Myeloma. Leuk."},{"key":"10.1016\/j.heliyon.2024.e39698_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/16078454.2021.1965737","article-title":"3-weekly daratumumab-lenalidomide\/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma","volume":"26","author":"Chim","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.heliyon.2024.e39698_bib35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jfma.2018.07.020","article-title":"Autologous stem cell transplantation in multiple myeloma: post-transplant outcomes of taiwan blood and marrow transplantation Registry","volume":"118","author":"Huang","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.heliyon.2024.e39698_bib36","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00432-019-02967-3","article-title":"A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients","volume":"145","author":"Li","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib37","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.leukres.2009.04.006","article-title":"Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience","volume":"33","author":"Zheng","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib38","first-page":"1","article-title":"Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients","volume":"2015","author":"Wu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2024.e39698_bib39","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ar.21218","article-title":"Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China","volume":"293","author":"Chen","year":"2010","journal-title":"Anat. Rec. Adv. Integr. Anat. Evol. Biol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22888","article-title":"Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function","volume":"33","author":"Chen","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.heliyon.2024.e39698_bib41","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e39698_bib42","first-page":"515","article-title":"The clinical characteristics and prognosis of IGH deletion in multiple myeloma, Leuk","volume":"39","author":"He","year":"2015","journal-title":"Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib43","first-page":"422","article-title":"Tolerance, kinetics, and depth of response for subcutaneous versus intravenous administration of bortezomib combination in Chinese patients with newly diagnosed multiple myeloma, clin. Lymphoma myeloma","volume":"18","author":"Xu","year":"2018","journal-title":"Leuk"},{"key":"10.1016\/j.heliyon.2024.e39698_bib44","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1177\/147323001103900544","article-title":"Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients","volume":"39","author":"Chen","year":"2011","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib45","first-page":"1656","article-title":"Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma, Cancer","volume":"10","author":"Xu","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.heliyon.2024.e39698_bib46","first-page":"118","article-title":"Lower dose dexamethasone\/thalidomide and zoledronic acid every 3 Weeks in previously untreated multiple myeloma, clin. Lymphoma. Myeloma","volume":"12","author":"Teoh","year":"2012","journal-title":"Leuk"},{"key":"10.1016\/j.heliyon.2024.e39698_bib47","first-page":"51","article-title":"Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma, clin. Lymphoma. Myeloma","volume":"10","author":"Zhou","year":"2010","journal-title":"Leuk"},{"key":"10.1016\/j.heliyon.2024.e39698_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jcla.23416","article-title":"Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients","volume":"34","author":"Chen","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.heliyon.2024.e39698_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12185-020-03044-z","article-title":"A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China","volume":"113","author":"Du","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/10245332.2016.1234186","article-title":"Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma","volume":"22","author":"Wang","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.heliyon.2024.e39698_bib52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s12253-014-9785-7","article-title":"Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma","volume":"20","author":"Zhang","year":"2014","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12185-021-03204-9","article-title":"Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial","volume":"114","author":"Suzuki","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0019-509X.38942","article-title":"Long term use of thalidomide: safe and effective","volume":"44","author":"Sharma","year":"2007","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e39698_bib55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/hon.2131","article-title":"Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival","volume":"32","author":"Chim","year":"2014","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib56","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA\u2010specific CAR T\u2010cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-bcma CAR T cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e39698_bib60","first-page":"273.e1","article-title":"Efficacy and safety of chimeric antigen receptor T-cell therapy for relapsed\/refractory Immunoglobulin D multiple myeloma, transplant","volume":"27","author":"Chen","year":"2021","journal-title":"Cell. Ther"},{"key":"10.1016\/j.heliyon.2024.e39698_bib61","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib62","first-page":"54","article-title":"Hematological, biochemical and renal changes in patients of multiple myeloma treated with bortezomib based triple drug chemotherapy","volume":"67","author":"Panda","year":"2019","journal-title":"J. Assoc. Physicians. India."},{"key":"10.1016\/j.heliyon.2024.e39698_bib63","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1245\/s10434-014-3754-y","article-title":"Partial tumor resection combined with chemotherapy for multiple myeloma spinal cord compression","volume":"21","author":"Qian","year":"2014","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1479-5876-8-124","article-title":"Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib\/thalidomide\/dexamethasone in transplant eligible patients","volume":"8","author":"Chim","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib65","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00277-012-1506-2","article-title":"Low incidence of thromboembolism in relapsed\/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan","volume":"91","author":"Wu","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib66","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-017-3310-0","article-title":"Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed\/refractory multiple myeloma: a phase 2 study","volume":"79","author":"Leng","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/07357900701208808","article-title":"Randomized phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma","volume":"25","author":"Chiou","year":"2007","journal-title":"Cancer Invest."},{"key":"10.1016\/j.heliyon.2024.e39698_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1477-7819-12-234","article-title":"Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study","volume":"12","author":"Zhang","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00432-013-1570-6","article-title":"How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study","volume":"140","author":"Huang","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib70","article-title":"Higher decorin levels in bone marrow plasma are associated with superior treatment response to novel agent-based induction in patients with newly diagnosed myeloma - a retrospective study, plos","volume":"17","author":"Huang","year":"2015","journal-title":"ONE"},{"key":"10.1016\/j.heliyon.2024.e39698_bib71","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00277-020-04234-9","article-title":"Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study","volume":"99","author":"Li","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib72","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4103\/jcrt.JCRT_459_17","article-title":"Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: lesson from a tertiary cancer center in rural India","volume":"16","author":"Nair","year":"2020","journal-title":"J. Cancer. Res. Ther."},{"key":"10.1016\/j.heliyon.2024.e39698_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12957-015-0649-8","article-title":"Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report","volume":"13","author":"An","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib74","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.18632\/oncotarget.3319","article-title":"Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e39698_bib75","first-page":"140","article-title":"A report of 134 newly diagnosed multiple myeloma patients with renal impairment, acta","volume":"135","author":"Liu","year":"2016","journal-title":"Haematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib76","first-page":"1","article-title":"The applicability of the international staging system in Chinese patients with multiple myeloma receiving bortezomib or thalidomide-based regimens as induction therapy: a multicenter analysis","volume":"2015","author":"Lu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.heliyon.2024.e39698_bib77","article-title":"Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China","volume":"98","author":"Yao","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e39698_bib78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/ejh.13440","article-title":"IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients","volume":"105","author":"Mao","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106710","article-title":"Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma","volume":"110","author":"Tang","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.heliyon.2024.e39698_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252124","article-title":"Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan","volume":"16","author":"Cheng","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e39698_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/1534735420943280","article-title":"Chinese herbal medicine is helpful for survival improvement in patients with multiple myeloma in taiwan: a nationwide retrospective matched-cohort study","volume":"19","author":"Huang","year":"2020","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.heliyon.2024.e39698_bib82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-016-2069-8","article-title":"Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma: MM-024 Extended Access Program","volume":"16","author":"Du","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e39698_bib83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12185-015-1771-7","article-title":"Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment","volume":"101","author":"Zhou","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib85","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.heliyon.2024.e39698_bib86","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s12325-014-0159-z","article-title":"Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients","volume":"31","author":"Lin","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.heliyon.2024.e39698_bib87","article-title":"Prognostic impact of cytogenetic abnormalities in multiple myeloma: a retrospective analysis of 229 patients","volume":"95","author":"Jian","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e39698_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23910","article-title":"PHD finger protein 19 expression in multiple myeloma: Association with clinical features, induction therapy outcome, disease progression, and survival","volume":"35","author":"Li","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.heliyon.2024.e39698_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22107","article-title":"Pretreatment neutrophil\/lymphocyte ratio but not platelet\/lymphocyte ratio has a prognostic impact in multiple myeloma","volume":"31","author":"Li","year":"2017","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.heliyon.2024.e39698_bib90","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00277-020-03915-9","article-title":"Early monoclonal protein decline pattern is an independent prognostic factor in patients with multiple myeloma","volume":"99","author":"Xu","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-017-3203-7","article-title":"CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens","volume":"97","author":"Qin","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib92","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0609.2012.01828.x","article-title":"Pre-existing diabetes mellitus in patients with multiple myeloma","volume":"89","author":"Chou","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib93","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.heliyon.2024.e39698_bib94","first-page":"394","article-title":"Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment, clin. Lymphoma","volume":"9","author":"Li","year":"2009","journal-title":"Myeloma"},{"key":"10.1016\/j.heliyon.2024.e39698_bib95","doi-asserted-by":"crossref","first-page":"8962","DOI":"10.1002\/cam4.3594","article-title":"Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients","volume":"23","author":"Bao","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib96","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/ejh.12434","article-title":"LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens","volume":"94","author":"Chim","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib97","doi-asserted-by":"crossref","DOI":"10.21037\/apm-21-3313","article-title":"Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study","volume":"10","author":"Huang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.heliyon.2024.e39698_bib98","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41598-020-80607-4","article-title":"Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e39698_bib99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-5-28","article-title":"Hong Kong Society of Myeloma, Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD","volume":"5","author":"Chim","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s12288-018-1026-x","article-title":"Myeloma at cross roads in India","volume":"34","author":"Yanamandra","year":"2018","journal-title":"Indian. J. Hematol. Blood. Transfus."},{"key":"10.1016\/j.heliyon.2024.e39698_bib102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e39698_bib103","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41416-019-0532-4","article-title":"Challenges of international oncology trial collaboration\u2014a call to action","volume":"121","author":"Tang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e39698_bib104","first-page":"939","article-title":"Complete response after autologous stem cell transplant in multiple myeloma, Cancer","volume":"3","author":"Kumar","year":"2014","journal-title":"Med"},{"key":"10.1016\/j.heliyon.2024.e39698_bib105","doi-asserted-by":"crossref","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","article-title":"Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study","volume":"21","author":"Fu","year":"2021","journal-title":"Clin. Lymphoma. Myeloma. Leuk."},{"key":"10.1016\/j.heliyon.2024.e39698_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e39698_bib107","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.critrevonc.2017.03.018","article-title":"Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: a meta-analysis of phase III randomized controlled trials","volume":"113","author":"Sun","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.heliyon.2024.e39698_bib108","first-page":"377","article-title":"Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma, Oncol","volume":"13","author":"Huang","year":"2019","journal-title":"Rev."},{"key":"10.1016\/j.heliyon.2024.e39698_bib109","first-page":"84","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement, Blood","volume":"11","author":"Teoh","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.heliyon.2024.e39698_bib110","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood. Adv."},{"key":"10.1016\/j.heliyon.2024.e39698_bib111","first-page":"161","article-title":"Extramedullary disease in multiple myeloma, Blood","volume":"11","author":"Bansal","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.heliyon.2024.e39698_bib112","first-page":"1","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review, Blood","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Cancer J."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024157295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024157295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:23:44Z","timestamp":1775456624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024157295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":111,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2405844024157295"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39698","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e39698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e39698"}}